Key result
A review of current treatments and potential targetable pathways for retroperitoneal dedifferentiated liposarcoma highlights the need for new targeted therapies due to low survival and high recurrence.
Why the study?
Abdominal liposarcoma carries high recurrence and low 10-year overall survival, systemic therapies have low response rates, and understanding oncologic drivers is needed to develop targeted therapies.
This review highlights the need for and potential of new targeted therapies for retroperitoneal dedifferentiated liposarcoma, a disease with poor survival and high recurrence rates.
Answers are grounded in this paper and cite their sources.
Limited options persist for retroperitoneal dedifferentiated liposarcoma; leaves open whether targeted pathways can improve survival in trials.
Liposarcoma (LPS) is the most prevalent soft tissue sarcoma histological subtype. When it occurs in the abdomen the overall survival rate is as low as 10% at 10 years and is fraught with high rates of recurrence, particularly for the more aggressive dedifferentiated subtype. Surgery remains the mainstay of treatment. Systemic therapies for the treatment of metastatic or unresectable disease have low response rates. Deep understanding of well-differentiated and de-differentiated LPS (WDLPS and DDLPS, respectively) oncologic drivers is necessary for the development of new efficacious targeted therapies for the management of this disease. This review discusses the current treatments under evaluation for retroperitoneal DDLPS and the potential targetable pathways in DDLPS.
No takes yet. Share an insight, caveat, or question.
Casadei et al. (2022) conducted a review in Retroperitoneal Liposarcoma. Targeted therapies was evaluated. A review of current treatments and potential targetable pathways for retroperitoneal dedifferentiated liposarcoma highlights the need for new targeted therapies due to low survival and high recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: